MIF098

MIF098 is a macrophage migration inhibitory factor ( MIF ) antagonist. MIF098 inhibits proliferation, migration and fibrosis of pulmonary smooth muscle cells. MIF098 can be used for immunoinflammation-related disease research. In Vitro MIF098 (0-10 μM, 48 h) inhibits mPASMC cell proliferation and migration in a concentration-dependent manner, by blocking the migration inhibitory factor (MIF) pathway. MIF098 reduces collagen synthesis and pulmonary artery fibrosis by inhibiting the TGFβ1/Smad2/3 pathway. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Mouse pulmonary artery smooth muscle cells (mPASMCs) Concentration: 0-10 μM Incubation Time: 48 hours Result: Reduced expression of cell cycle related proteins such as cyclin D1, CDK4 and CDK6 in PDGF-BB and increased expression of cell-cycle arrest proteins such as P53 and P21. Reduced TGFβ1-induced fibronectin (FN), collagen I (col I), and collagen II (col II) expression and phosphorylation of Smad2 and Smad3. In Vivo MIF098 (intraperitoneal injection, 40 mg/kg, once a day, 4 weeks) attenuates the process of hypoxia-induced pulmonary arterial hypertension in C57BL/6J mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Hypoxic male C57BL/6J mice Dosage: 40 mg/kg Administration: Intraperitoneal injection; once a day; 4 weeks Result: Reduced right ventricular systolic pressure (RVSP), percentage medial wall thickness, muscularization and right ventricle collagen deposition. Decreased percentage of collagen fibers in pulmonary artery (PA). Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet